Two distinct cases with COVID-19 in kidney transplant recipients
- Author(s)
- Yaerim Kim; Ohyun Kwon; Jin H. Paek; Woo Y. Park; Kyubok Jin; Miri Hyun; Ji Y. Lee; Hyun A. Kim; Seungyeup Han
- Keimyung Author(s)
- Kim, Yae Rim; Paek, Jin Hyuk; Park, Woo Young; Jin, Kyu Bok; Hyun, Mi Ri; Lee, Ji Yeon; Kim, Hyun Ah; Han, Seung Yeup
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
- Issued Date
- 2020
- Volume
- 20
- Issue
- 8
- Keyword
- clinical research/practice; immunosuppressant; infection and infectious agents – viral; infectious disease; kidney (allograft) function/dysfunction; kidney transplantation/nephrology
- Abstract
- The fatality of novel coronavirus disease 2019 (COVID‐19) is precipitously increased in patients with underlying comorbidities or elderly people. Kidney transplant (KT) recipients are one of the vulnerable populations for infection. COVID‐19 infection in KT recipients might be a complicated and awkward situation, but there has been a lack of reports concerning this group. Herein, we demonstrated two distinct cases with different clinical progress. The first case was a 36‐year‐old man who underwent KT 3 years ago. He was diagnosed with COVID‐19 expressing relevant symptoms. Following administration of lopinavir/ritonavir and hydroxychloroquine with reduced immunosuppressant, he recovered from COVID‐19. However, the unexpected fluctuations in tacrolimus trough levels needed to be managed because of drug‐to‐drug interaction. The second case was developed in a 56‐year‐old man without any symptoms. He received a second KT from an ABO‐incompatible donor 8 years ago. He was diagnosed with COVID‐19 by screening due to exposure history. During the hospitalization period, the chest infiltrative lesion showed a wax and wane, but he successfully recovered by administration of hydroxychloroquine with azithromycin. These apparently different cases suggest that assertive screening and management could improve the clinical course. In addition, antiviral agents should be used cautiously, especially in patients on calcineurin inhibitors.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.